2022

Fluoroquinolones for systemic or inhaled use (OFLOXACIN EURO, LEVOFLOXACIN EURO) – reminder of restrictions on use (risk of long-lasting serious adverse reactions)

Important information on minimizing the risk of aortic aneurysm and dissection and cardiac valve regurgitation/insufficiency with the use of systemic and inhaled fluoroquinolones

Reminder for healthcare professionals about the Stamaril vaccine: indications, contraindications, recommendations and features of use to ensure a proper assessment of the individual benefit/risk ratio before vaccinating a patient

Information letter for healthcare professionals on the update of the package leaflet for the yellow fever vaccine. Contains a reminder of the indications, contraindications and special considerations for use, for a proper assessment of the benefit/risk balance before vaccinating a patient. generated automatically

EPIPEN

The video is educational and is not used for advertising purposes. This video cannot be played in your browser. Download video7:45 · 27.8…

VORICONAZOLE ZENTIVA

Educational Q&A brochure for healthcare professionals on the safe use of the medicinal product Voriconazole Zentiva. Contains information on the risks of phototoxicity, squamous cell carcinoma of the skin, and hepatotoxicity, as well as recommendations on their monitoring, management, and informing patients. compiled automatically

Lemtrada

Educational checklist for healthcare professionals on the use of the medicinal product Lemtrada (alemtuzumab): contains a list of contraindications, recommended examinations, tests, vaccinations and risk minimization measures at different stages of treatment. generated automatically

Metamizole: risk of drug-induced liver injury

Dexmedetomidine: increased mortality risk in intensive care unit patients aged ≤ 65 years

Informational letter to healthcare professionals on the increased risk of mortality in intensive care unit patients under 65 years of age during sedation with dexmedetomidine, based on the results of the SPICE III study. It describes the evidence, updates to the package insert, and the procedure for reporting adverse reactions. generated automatically

Important information on minimizing the risks of teratogenicity and the development of other primary malignancies with the use of lenalidomide

Information notification letter for healthcare professionals on the important risks of using lenalidomide — teratogenicity and the development of other primary malignancies — and measures to minimize them. It contains a brief summary of safety and the indications for use of the medicinal product. generated automatically

Important information on minimizing the risk of severe and life-threatening adverse reactions with the use of the medicinal product FLUOROURACILVISTA in patients with partial or complete dihydropyrimidine dehydrogenase deficiency

Information letter-notification for healthcare professionals on minimizing the risk of severe and life-threatening adverse reactions when using a fluorouracil-containing medicinal product in patients with partial or complete dihydropyrimidine dehydrogenase deficiency, with recommendations for testing the level of this enzyme before starting treatment. compiled automatically